Choreo LLC decreased its position in Insulet Co. (NASDAQ:PODD - Free Report) by 93.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,239 shares of the medical instruments supplier's stock after selling 30,996 shares during the quarter. Choreo LLC's holdings in Insulet were worth $590,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Yousif Capital Management LLC grew its position in Insulet by 15.4% during the fourth quarter. Yousif Capital Management LLC now owns 11,652 shares of the medical instruments supplier's stock worth $3,042,000 after buying an additional 1,554 shares in the last quarter. Sargent Investment Group LLC acquired a new stake in Insulet during the fourth quarter worth approximately $256,000. Mather Group LLC. grew its position in Insulet by 6.6% during the fourth quarter. Mather Group LLC. now owns 870 shares of the medical instruments supplier's stock worth $227,000 after buying an additional 54 shares in the last quarter. Alliance Wealth Advisors LLC UT grew its position in Insulet by 7.8% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 3,263 shares of the medical instruments supplier's stock worth $852,000 after buying an additional 235 shares in the last quarter. Finally, Jennison Associates LLC grew its position in Insulet by 21.8% during the fourth quarter. Jennison Associates LLC now owns 158,342 shares of the medical instruments supplier's stock worth $41,338,000 after buying an additional 28,375 shares in the last quarter.
Insulet Trading Down 0.6 %
NASDAQ PODD traded down $1.56 on Friday, reaching $280.56. The company had a trading volume of 474,733 shares, compared to its average volume of 528,501. The firm has a market cap of $19.68 billion, a price-to-earnings ratio of 48.04, a P/E/G ratio of 3.61 and a beta of 1.23. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The business has a 50 day moving average of $271.74 and a two-hundred day moving average of $244.03. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.
Insider Activity at Insulet
In other Insulet news, CAO Lauren Budden sold 915 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.
Analyst Ratings Changes
PODD has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their price target on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research report on Thursday, December 12th. TD Cowen increased their price target on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Barclays increased their price target on Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a research report on Monday, November 11th. Wells Fargo & Company upped their target price on Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Finally, Sanford C. Bernstein initiated coverage on Insulet in a research note on Wednesday, November 6th. They set an "outperform" rating and a $300.00 target price for the company. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average price target of $277.13.
Read Our Latest Report on Insulet
Insulet Profile
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Featured Stories
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
